Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
26.48
+0.80 (3.12%)
At close: Jul 13, 2026, 4:00 PM EDT
26.57
+0.09 (0.34%)
Pre-market: Jul 14, 2026, 8:12 AM EDT

Denali Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4,2032,5792,9392,9703,7815,454
Market Cap Growth
99.64%-12.27%-1.03%-21.46%-30.67%-45.98%
Enterprise Value
3,1911,7432,1491,9802,4984,647
Last Close Price
26.4816.5120.3821.4627.8144.60
Forward PE
-46.4646.4646.4646.4646.46
PS Ratio
---8.98--
PB Ratio
4.542.542.392.883.635.67
P/TBV Ratio
5.252.812.732.863.355.63
EV/Sales Ratio
---5.99--
Debt / Equity Ratio
0.030.030.030.040.050.06
Net Debt / Equity Ratio
-1.03-0.82-0.64-0.96-1.23-0.84
Net Debt / EBITDA Ratio
1.791.541.655.503.882.81
Net Debt / FCF Ratio
2.281.982.172.674.893.67
Asset Turnover
-000.2500
Quick Ratio
8.978.828.1413.273.672.29
Current Ratio
9.289.168.4613.653.772.37
Return on Equity (ROE)
-52.38%-45.69%-37.40%-14.01%-32.52%-27.51%
Return on Assets (ROA)
-45.39%-44.10%-38.56%-15.05%-23.79%-19.62%
Return on Invested Capital (ROIC)
-743.24%-179.68%-202.65%---
Return on Capital Employed (ROCE)
-49.68%-47.91%-41.51%-18.11%-32.11%-23.12%
Buyback Yield / Dilution
-3.87%-4.97%-19.73%-9.43%-3.30%-7.83%
Total Shareholder Return
-3.87%-4.97%-19.73%-9.43%-3.30%-7.83%
SEC Filings: 10-K · 10-Q